Celadon Pharmaceuticals
UK-listed medical cannabis cultivator and pharmaceutical developer with Home Office cultivation licence.
Celadon Pharmaceuticals is documented as a UK-listed company with a Home Office cultivation licence for high-THC cannabis, but independent verification of its operational scale, product volumes, clinical trial progress, or financial performance is limited. Claims should be checked against audited filings and regulatory announcements rather than marketing materials. The cannabis industry includes many small-cap companies with shifting timelines and significant share volatility.
What we could verify
Celadon Pharmaceuticals plc is listed on the London Stock Exchange's AIM market (ticker CEL) and admitted in 2022 [1]. Company announcements and regulatory filings indicate the company holds a Home Office cultivation licence to grow high-THC cannabis at a site in the UK and has described operating a GMP-compliant facility [1]. The company has announced clinical research activities related to cannabis-based medicine development [1]. Beyond these public regulatory filings and company announcements, independent verification of operational volumes, prescription numbers, trial progress, or market share is not readily available in peer-reviewed literature or independent journalism. Investors and patients should review the most recent audited annual report and RNS regulatory announcements via the London Stock Exchange before relying on any operational or financial claims.
What the name suggests (and why that is not evidence)
The name 'Celadon Pharmaceuticals' appears to be a company trading name with no widely documented connection to specific cannabis cultivars, a breeder identity, or a product lineup independent of company filings. In the cannabis industry, strain and product names are often trademarked, rebranded or shared across multiple producers without clear lineage or consistent cannabinoid profiles Anecdote. A company name or stock ticker is not the same as independent documentation of product identity, potency, or quality. If you encounter 'Celadon' as a strain name or product claim, verify it against a current certificate of analysis (COA) from a UK accredited laboratory and the prescribing pharmacy's records, not against the company name alone.
How to verify before use or investment
Regulatory and financial status:
- Check the London Stock Exchange for Celadon Pharmaceuticals plc (CEL) current listing status, trading suspension alerts, and regulatory announcements (RNS) [1].
- Review the company's latest audited annual report and financial statements filed with Companies House to confirm operational activity and reported revenue/prescriptions.
- Confirm Home Office cultivation licence validity through the company's public filings; licences are time-limited and site-specific.
Clinical and product claims:
- Search ClinicalTrials.gov and ISRCTN for any cannabis-related trials sponsored by Celadon; trial registrations and published results are authoritative, press releases are not Weak / limited.
- If a specific product is prescribed, request a certificate of analysis from the pharmacy; UK test results must be from an accredited laboratory and state cannabinoid content, residual solvents, and microbial status.
Medical and prescription access:
- Cannabis-based products in the UK can only be prescribed by registered specialists on the GMC Specialist Register. Verify the prescriber's GMC status and the pharmacy's accreditation [2].
- Celadon products do not sell directly to consumers; all supply is via registered pharmacy channels.
Similar documented brands and resources
Other UK and international medical cannabis companies and ancillary brands with published operational records include Cronos Group, Jushi Holdings, and SNDL Inc.. For independent information on cannabis testing, cultivation science, and cannabinoid pharmacology, consult peer-reviewed literature and regulatory guidance from the MHRA and Department of Health & Social Care rather than company marketing.
Report missing or incorrect information
If you have verifiable documentation of Celadon Pharmaceuticals' breeder records, ownership structure, operational milestones, laboratory test results, clinical trial outcomes, or other factual information not yet in this profile, please submit it via the 'Flag an error' tool. Submissions should include a specific, stable source (peer-reviewed paper with DOI, government agency page, RNS announcement, audited financial filing, or trial registration) and the claim or correction. Anecdotal reports of product quality or effects are welcome in community forums but cannot update this brand profile without independent verification No data.
Sources
- Government London Stock Exchange. Celadon Pharmaceuticals plc (CEL) – Company Information Page. AIM Market.
- Government Medicines and Healthcare products Regulatory Agency (MHRA) and Department of Health & Social Care. Cannabis-based products for medicinal use in humans (CBPMs): supply, manufacture, importation and distribution guidance.
- Peer-reviewed Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018). Medical cannabis: a systematic review of chemical constituents, adverse effects and systemic effects. Journal of Clinical Medicine, 7(12), 534.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cronos Group — Toronto-based public cannabis company with Altria as largest shareholder, selling adult-us...
- Jushi Holdings — Publicly traded US cannabis operator with retail and cultivation in multiple state markets...
- SNDL Inc. — Canadian multi-segment cannabis, liquor retail, and investment holding company.